Business Description
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
Business History
Price Overview
Last updated: Jun 27, 2026 10:05am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.46
Total Equity: $778.20M
Shares: 46,400,000
Total Debt: $100.50M
Cash: $89.80M
EBITDA: -$33.20M
Total Debt: $100.50M
Cash: $89.80M
Revenue: $701.20M
Shares: 46,400,000
Revenue: $701.20M
Revenue: $701.20M
Revenue: $701.20M
Total Equity: $778.20M
Tax Rate: -2.6%
Equity: $778.20M
Total Debt: $100.50M
Cash: $89.80M
Current Liabilities: $165.20M
Long-Term Debt: $90.30M
Total Debt: $100.50M
Total Equity: $778.20M
Shares: 46,400,000
Shares: 46,400,000
CapEx: -$31.60M
Shares: 46,400,000
Stock Price: $24.95
Net Income: -$67.90M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $744.6M | $684.1M | $673.3M | $687.8M | $701.2M |
| Cost of Revenue | $364.7M | $289.9M | $293.6M | $306.5M | $352.2M |
| Gross Profit | $379.9M | $394.2M | $379.7M | $381.3M | $349.0M |
| Operating Expenses | $293.1M | $352.3M | $314.7M | $341.3M | $410.6M |
| Operating Income | $86.8M | $41.9M | $65.0M | $40.0M | -$61.6M |
| Net Income | $6.3M | $50.5M | -$61.8M | -$392.1M | -$67.9M |
| EBITDA | $48.9M | $77.8M | $50.6M | -$345.6M | -$33.2M |
| EPS | $0.13 | $1.08 | $-1.33 | $-8.53 | $-1.46 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $118.5M | $127.7M | $87.7M | $107.7M | $89.8M |
| Total Current Assets | $427.6M | $624.1M | $487.0M | $393.4M | $355.4M |
| Total Assets | $1.6B | $1.8B | $1.7B | $1.2B | $1.1B |
| Current Liabilities | $139.2M | $191.0M | $234.6M | $165.9M | $165.2M |
| Long-Term Debt | $130.0M | $226.3M | $159.4M | $125.3M | $90.3M |
| Total Liabilities | $333.0M | $495.7M | $456.1M | $325.7M | $295.5M |
| Total Equity | $1.3B | $1.3B | $1.2B | $828.5M | $778.2M |
| Retained Earnings | -$303.6M | -$253.1M | -$314.9M | -$707.0M | -$779.9M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $87.3M | $90.9M | $32.4M | $100.7M | $74.7M |
| Capital Expenditure | -$21.0M | -$19.3M | -$17.8M | -$17.8M | -$31.6M |
| Free Cash Flow | $66.3M | $71.6M | $14.6M | $82.9M | $43.1M |
| Acquisitions (net) | $0 | -$116.1M | $39.4M | -$9.7M | -$28.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$11.5M | -$45.5M | -$19.1M | -$12.8M | -$3.3M |
| Net Change in Cash | $7.0M | $9.2M | -$40.0M | $20.0M | -$17.9M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 7:42pm (14h ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$685.5M $685.4M – $685.5M
|
$695.0M $695.0M – $695.0M
|
$710.0M $710.0M – $710.0M
|
$740.0M $740.0M – $740.0M
|
| EBITDA |
-$40.5M -$40.5M – -$40.5M
|
-$41.0M -$41.0M – -$41.0M
|
-$41.9M -$41.9M – -$41.9M
|
-$43.7M -$43.7M – -$43.7M
|
| Net Income |
$61.5M $61.0M – $61.9M
|
$41.8M $41.8M – $41.8M
|
$46.4M $46.4M – $46.4M
|
$58.0M $58.0M – $58.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -8.1% | -1.6% | +2.2% | +1.9% |
| Gross Profit Growth | +3.8% | -3.7% | +0.4% | -8.5% |
| Operating Income Growth | -51.7% | +55.1% | -38.5% | -254.0% |
| Net Income Growth | +701.6% | -222.4% | -534.5% | +82.7% |
| EBITDA Growth | +59.1% | -35.0% | -783.0% | +90.4% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-08 | BLACKFORD GARY | A-Award | 12,003.00 | $0.00 | $0 |
| 2026-05-08 | Egbuonu-Davis Lisa | A-Award | 12,003.00 | $0.00 | $0 |
| 2026-05-08 | Franchini Indrani Lall | A-Award | 12,003.00 | $0.00 | $0 |
| 2026-05-08 | OLEARY PATRICK J | A-Award | 12,003.00 | $0.00 | $0 |
| 2026-05-08 | Shimer Julie Ann | A-Award | 12,003.00 | $0.00 | $0 |
| 2026-04-22 | Galovan Scott Michael | F-InKind | 4,228.00 | $24.64 | $104,178 |
| 2026-04-22 | Delgado Sigfrido | F-InKind | 4,264.00 | $24.64 | $105,065 |
| 2026-04-14 | Pacitti David | F-InKind | 21,194.00 | $14.53 | $307,949 |
| 2026-03-13 | Delgado Sigfrido | A-Award | 37,782.00 | $13.69 | $517,236 |
| 2026-03-13 | Pacitti David | A-Award | 241,021.00 | $13.69 | $3.3M |
| 2026-03-13 | Galovan Scott Michael | A-Award | 70,115.00 | $13.69 | $959,874 |
| 2026-03-13 | Hurley John Joseph | A-Award | 2,211.00 | $0.00 | $0 |
| 2026-03-13 | Galovan Scott Michael | A-Award | 29,481.00 | $0.00 | $0 |
| 2026-03-13 | Galovan Scott Michael | A-Award | 69,630.00 | $13.69 | $953,235 |
| 2026-03-13 | Pacitti David | A-Award | 101,341.00 | $0.00 | $0 |
| 2026-03-13 | Pacitti David | A-Award | 239,354.00 | $13.69 | $3.3M |
| 2026-03-13 | Delgado Sigfrido | A-Award | 15,886.00 | $0.00 | $0 |
| 2026-03-13 | Delgado Sigfrido | A-Award | 37,520.00 | $13.69 | $513,649 |
| 2026-03-09 | Hurley John Joseph | F-InKind | 226.00 | $13.29 | $3,004 |
| 2026-03-09 | Galovan Scott Michael | F-InKind | 1,119.00 | $13.29 | $14,872 |
Narrative Economics
market-narrative step).